ACE-041

· Acceleron Pharma, Inc. (a wholly-owned subsidiary of Merck & Co., Inc.)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ACE-041, covering 2013-03-18 to 2013-03-18. Get the full timeline:

Most recent: Clinical Trial Update: Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma [Phase 1]